Literature DB >> 20882670

Autoimmune-mediated reduction of high-density lipoprotein-cholesterol and paraoxonase 1 activity in systemic lupus erythematosus-prone gld mice.

Roshni Srivastava1, Shaohua Yu, Brian W Parks, Leland L Black, Janusz H Kabarowski.   

Abstract

OBJECTIVE: To characterize modifications of high-density lipoprotein (HDL) in autoimmune gld mice that may be relevant to premature atherosclerosis in systemic lupus erythematosus, and to assess their relationship to specific aspects of autoimmune disease.
METHODS: HDL cholesterol (HDL-C), apolipoprotein A-I (Apo A-I), paraoxonase 1 (PON1) activity, hepatic gene expression, and HDL biogenesis were measured in aging female gld and wild-type congenic mice. Autoantibodies, lymphoid organs, and cytokines were analyzed by enzyme-linked immunosorbent assay, flow cytometry, and multiplex assay, respectively.
RESULTS: Plasma HDL-C, HDL Apo A-I, and HDL-associated PON1 activity were reduced in aging gld mice in association with the development of autoimmunity, independent of changes in hepatic Apo A-I and PON1 expression or HDL biogenesis. Hepatic induction of the acute-phase reactant serum amyloid A1 resulted in its incorporation into HDL in gld mice. Deletion of the lipid-sensitive receptor G2A in gld mice (G2A-/- gld) attenuated reductions in HDL-C and PON1 activity without altering hepatic Apo A-I and PON1 expression, HDL biogenesis, or levels of acute-phase proinflammatory cytokines. Plasma anti-Apo A-I autoantibodies were elevated in aging gld mice commensurate with detectable increases in Apo A-I immune complexes. Autoantibody levels were lower in aging G2A-/- gld mice compared with gld mice, and anti-Apo A-I autoantibody levels were significantly related to HDL-C concentrations (r=-0.645, P<0.00004) and PON1 activity (r=-0.555, P<0.0007) among autoimmune gld and G2A-/- gld mice.
CONCLUSION: Autoantibodies against Apo A-I contribute to reducing HDL-C and PON1 activity in autoimmune gld mice independently of hepatic HDL biogenesis, suggesting that functional impairment and premature clearance of HDL immune complexes may be principal mechanisms involved.
Copyright © 2011 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20882670      PMCID: PMC3032585          DOI: 10.1002/art.27764

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  48 in total

Review 1.  Mouse models of atherosclerosis.

Authors:  Alan Daugherty
Journal:  Am J Med Sci       Date:  2002-01       Impact factor: 2.378

2.  Regulation of scavenger receptor class B type I in hamster liver and Hep3B cells by endotoxin and cytokines.

Authors:  W Khovidhunkit; A H Moser; J K Shigenaga; C Grunfeld; K R Feingold
Journal:  J Lipid Res       Date:  2001-10       Impact factor: 5.922

3.  Mice lacking the orphan G protein-coupled receptor G2A develop a late-onset autoimmune syndrome.

Authors:  L Q Le; J H Kabarowski; Z Weng; A B Satterthwaite; E T Harvill; E R Jensen; J F Miller; O N Witte
Journal:  Immunity       Date:  2001-05       Impact factor: 31.745

4.  Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome.

Authors:  J Delgado Alves; P R J Ames; S Donohue; L Stanyer; J Nourooz-Zadeh; C Ravirajan; D A Isenberg; J Noorouz-Zadeh
Journal:  Arthritis Rheum       Date:  2002-10

5.  Expression of mouse acute-phase (SAA1.1) and constitutive (SAA4) serum amyloid A isotypes: influence on lipoprotein profiles.

Authors:  M S Kindy; M C de Beer; J Yu; F C de Beer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-06       Impact factor: 8.311

Review 6.  Apolipoprotein E: far more than a lipid transport protein.

Authors:  R W Mahley; S C Rall
Journal:  Annu Rev Genomics Hum Genet       Date:  2000       Impact factor: 8.929

7.  Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation.

Authors:  Orit Rozenberg; Diana M Shih; Michael Aviram
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-02-06       Impact factor: 8.311

Review 8.  Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host.

Authors:  Weerapan Khovidhunkit; Min-Sun Kim; Riaz A Memon; Judy K Shigenaga; Arthur H Moser; Kenneth R Feingold; Carl Grunfeld
Journal:  J Lipid Res       Date:  2004-04-21       Impact factor: 5.922

9.  Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus.

Authors:  Anna Cederholm; Elisabet Svenungsson; Dominique Stengel; Guo-Zhong Fei; A Graham Pockley; Ewa Ninio; Johan Frostegård
Journal:  Arthritis Rheum       Date:  2004-09

10.  ApoE-dependent modulation of HDL and atherosclerosis by G2A in LDL receptor-deficient mice independent of bone marrow-derived cells.

Authors:  Brian W Parks; Roshni Srivastava; Shaohua Yu; Janusz H S Kabarowski
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-01-22       Impact factor: 8.311

View more
  21 in total

Review 1.  Dendritic cells and aging: consequences for autoimmunity.

Authors:  Anshu Agrawal; Aishwarya Sridharan; Sangeetha Prakash; Harsh Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2012-01       Impact factor: 4.473

Review 2.  mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging.

Authors:  Andras Perl
Journal:  Ann N Y Acad Sci       Date:  2015-04-23       Impact factor: 5.691

3.  Cholesterol-Independent Suppression of Lymphocyte Activation, Autoimmunity, and Glomerulonephritis by Apolipoprotein A-I in Normocholesterolemic Lupus-Prone Mice.

Authors:  Leland L Black; Roshni Srivastava; Trenton R Schoeb; Ray D Moore; Stephen Barnes; Janusz H Kabarowski
Journal:  J Immunol       Date:  2015-10-14       Impact factor: 5.422

Review 4.  The problem of accelerated atherosclerosis in systemic lupus erythematosus: insights into a complex co-morbidity.

Authors:  N S Wade; A S Major
Journal:  Thromb Haemost       Date:  2011-10-06       Impact factor: 5.249

5.  Association Between ApoA-I (Apolipoprotein A-I) Immune Complexes and Adverse Cardiovascular Events-Brief Report.

Authors:  David Henson; Ayman Samman Tahhan; David Nardo; Arshed Ali Quyyumi; Vincent J Venditto
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-07-18       Impact factor: 8.311

6.  Apolipoprotein a-I at the interface of vascular inflammation and arthritis.

Authors:  Robert Terkeltaub
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-03       Impact factor: 8.311

Review 7.  ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease.

Authors:  Dimitry A Chistiakov; Alexander N Orekhov; Yuri V Bobryshev
Journal:  Lab Invest       Date:  2016-05-16       Impact factor: 5.662

8.  CD36, but not G2A, modulates efferocytosis, inflammation, and fibrosis following bleomycin-induced lung injury.

Authors:  Brian W Parks; Leland L Black; Kurt A Zimmerman; Allison E Metz; Chad Steele; Joanne E Murphy-Ullrich; Janusz H Kabarowski
Journal:  J Lipid Res       Date:  2013-02-06       Impact factor: 5.922

Review 9.  Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity.

Authors:  Nicolas Vuilleumier; Fabrizio Montecucco; Oliver Hartley
Journal:  World J Cardiol       Date:  2014-05-26

Review 10.  Cardiovascular disease in lupus: insights and updates.

Authors:  Jason S Knight; Mariana J Kaplan
Journal:  Curr Opin Rheumatol       Date:  2013-09       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.